Global Polycystic Ovary Syndrome (PCOS) Drugs Market Revenue is Estimated to Reach US$ 1,154.8 mn by 2024 - PMR

NEW YORK, September 20, 2016 /PRNewswire/ --

Some of the Leading Companies in PCOS Drugs Market are Sanofi, Novartis, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and AstraZeneca Plc. 

According to the latest market report published by Persistence Market Research titled "Polycystic Ovary Syndrome Drugs Market", the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016-2024 and is expected to expand 1.5x in terms of revenue by 2024.

Growth of the global polycystic ovary syndrome drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. Increasing purchasing power among people and rising awareness of PCOS are factors expected to drive growth of the global PCOS drugs market. The need for effective management of diseases associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand for PCOS drugs.

View Report Table of Contents, Figures, and Tables at http://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market/toc

The global market for PCOS drugs presents several growth opportunities for market players. There is a good growth potential in emerging markets and pharmaceutical drugs manufacturers are focusing on emerging economies in the Asia Pacific and Africa such as Kenya, Nigeria, etc. to target a large patient population. Also, effective reimbursement policies and reduction in the costs of drugs used for the treatment of PCOS is likely to increase the adoption of PCOS drugs across the globe. Leading market players are also investing significantly in developing new branded drugs to treat PCOS, owing to an anticipated high rise in the global patient population. The demand for branded PCOS drugs is likely to increase significantly during the forecast period.

By Distribution Channel, the hospital pharmacies segment is likely to lead the global PCOS drugs market in terms of revenue growth and is estimated to be valued at US$ 575.4 Mn by the end of 2024. In terms of value, the drugs stores/OTC segment is estimated to account for 27.0% share of the overall market by the end of 2016.

Browse Full Report Overview at http://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market.asp

PCOS drugs market press release at http://www.persistencemarketresearch.com/mediarelease/polycystic-ovarian-syndrome-drugs-market.asp

On the basis of region, the North America market is expected to emerge as the dominant market for polycystic ovary syndrome drugs owing to a high diagnosis rate and increasing adoption of prescription drugs. North America is estimated to dominate the PCOS drugs market with maximum value share of the overall market by the end of 2016. The presence of well-established pharmaceutical companies in North America as well as a relatively high instance of patients being diagnosed in hospitals for PCOS is a major driver for market growth. The market in the Asia Pacific region is expected to register the highest CAGR of 5.5% over the forecast period. Significant increase in healthcare services spending along with rapid economic growth and increasing awareness about health issues are some of the key factors likely to push the sales of PCOS drugs in the APAC market.

View Sample Report at http://www.persistencemarketresearch.com/samples/3682

About Us: 

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
United States
USA - Canada Toll-Free: 800-961-0353
Email: [email protected]

Web: http://www.persistencemarketresearch.com
Blog: https://pmrblog.com

SOURCE Persistence Market Research Pvt. Ltd.